Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study

Key Points

• The research aims to assess how guselkumab affects patient-reported outcomes in individuals with psoriatic arthritis who did not respond adequately to TNF inhibitors.
• Conducted a clinical trial (COSMOS Study) with participants having inadequate response to TNF inhibitors.
• Administered guselkumab to assess its impact on patient-reported outcomes.
• Evaluated outcomes using standardized questionnaires before and after treatment.
• Participants reported significant improvements in symptoms and overall quality of life after treatment with guselkumab.
• The improvements were evident in multiple domains of patient-reported outcomes.
• Guselkumab demonstrated a more favorable response than previous TNF inhibitor therapies.